Mesenchymal stem cells reciprocally regulate the M1/M2 balance in mouse bone marrow-derived macrophages
2014 · Experimental & Molecular Medicine · 538 citations
https://doi.org/10.1038/emm.2013.135
Y
Youngkeun Ahn
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.2K
Papers
17.4K
Citations
58
h-index
394
i10-index
Youngkeun Ahn is an academic researcher from Chonnam National University. The author has contributed to research in topics: Coronary Interventions and Diagnostics & Acute Myocardial Infarction Research & Cardiac Imaging and Diagnostics. The author has an h-index of 58, co-authored 1041 publications.
ORCID: 0000-0003-2022-9366Papers by this author
worksPreventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial
2024 · The Lancet · 212 citations
https://doi.org/10.1016/s0140-6736(24)00413-6
Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial
2024 · The Lancet · 212 citations
https://doi.org/10.1016/s0140-6736(24)00413-6
Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial
2021 · The Lancet · 177 citations
https://doi.org/10.1016/s0140-6736(21)01445-8
Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial
2021 · The Lancet · 177 citations
https://doi.org/10.1016/s0140-6736(21)01445-8
ENOblock, a unique small molecule inhibitor of the non-glycolytic functions of enolase, alleviates the symptoms of type 2 diabetes
2017 · Scientific Reports · 64 citations
https://doi.org/10.1038/srep44186
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat